SK Bioscience Expands and Reorganizes IR Division into 'Value Innovation Office'

SK Bioscience.

[Asia Economy Reporter Lee Gwan-joo] SK Bioscience announced on the 1st that it will expand and reorganize its IR Office, which was previously responsible for corporate presentations, into the 'Value Innovation Office.'

Additionally, Song Ki-seok, a former official at the Bank of Korea and Merrill Lynch, was appointed as the new head of the Value Innovation Office. Song will also concurrently serve as the head of the Value Innovation Office at SK Discovery, the holding company.

SK Bioscience explained that this organizational restructuring was decided to enhance corporate value and drive value innovation in line with the rapidly growing business scope and scale, including securing vaccine sovereignty by obtaining approval for 'Skycovione,' Korea's first domestically produced COVID-19 vaccine, and establishing itself as a global vaccine hub.

The Value Innovation Office will be responsible for various tasks to innovate corporate value as a global top-tier vaccine company, including existing corporate disclosure and research duties, ▲advancing the holding company's governance structure ▲defining key financial indicators aligned with efforts to improve capital efficiency ▲selecting major financial investment targets ▲securing strategic investors.